Hypercholesterolemia - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 243 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hypercholesterolemia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Hypercholesterolemia - Pipeline Review, H1 2016', provides an overview of the Hypercholesterolemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hypercholesterolemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypercholesterolemia
- The report reviews pipeline therapeutics for Hypercholesterolemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hypercholesterolemia therapeutics and enlists all their major and minor projects
- The report assesses Hypercholesterolemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hypercholesterolemia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
Introduction 6
Hypercholesterolemia Overview 7
Therapeutics Development 8
Hypercholesterolemia - Therapeutics under Development by Companies 10
Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes 14
Hypercholesterolemia - Pipeline Products Glance 15
Hypercholesterolemia - Products under Development by Companies 19
Hypercholesterolemia - Products under Investigation by Universities/Institutes 24
Hypercholesterolemia - Companies Involved in Therapeutics Development 25
Hypercholesterolemia - Therapeutics Assessment 61
Drug Profiles 76
Hypercholesterolemia - Recent Pipeline Updates 169
Hypercholesterolemia - Dormant Projects 217
Hypercholesterolemia - Discontinued Products 223
Hypercholesterolemia - Product Development Milestones 225
Appendix 234

List of Tables

Number of Products under Development for Hypercholesterolemia, H1 2016 16
Number of Products under Development for Hypercholesterolemia - Comparative Analysis, H1 2016 17
Number of Products under Development by Companies, H1 2016 19
Number of Products under Development by Companies, H1 2016 (Contd..1) 20
Number of Products under Development by Companies, H1 2016 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H1 2016 22
Comparative Analysis by Late Stage Development, H1 2016 23
Comparative Analysis by Clinical Stage Development, H1 2016 24
Comparative Analysis by Early Stage Development, H1 2016 25
Comparative Analysis by Unknown Stage Development, H1 2016 26
Products under Development by Companies, H1 2016 27
Products under Development by Companies, H1 2016 (Contd..1) 28
Products under Development by Companies, H1 2016 (Contd..2) 29
Products under Development by Companies, H1 2016 (Contd..3) 30
Products under Development by Companies, H1 2016 (Contd..4) 31
Products under Investigation by Universities/Institutes, H1 2016 32
Hypercholesterolemia - Pipeline by 3SBio Inc., H1 2016 33
Hypercholesterolemia - Pipeline by Abeome Corporation, H1 2016 34
Hypercholesterolemia - Pipeline by Aegerion Pharmaceuticals, Inc., H1 2016 35
Hypercholesterolemia - Pipeline by AFFiRiS AG, H1 2016 36
Hypercholesterolemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 37
Hypercholesterolemia - Pipeline by Alvogen Korea Co., Ltd., H1 2016 38
Hypercholesterolemia - Pipeline by AtheroNova Inc., H1 2016 39
Hypercholesterolemia - Pipeline by BioLingus AG, H1 2016 40
Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016 41
Hypercholesterolemia - Pipeline by Cerenis Therapeutics Holding SA, H1 2016 42
Hypercholesterolemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 43
Hypercholesterolemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016 44
Hypercholesterolemia - Pipeline by Daewon Pharm Co. Ltd., H1 2016 45
Hypercholesterolemia - Pipeline by Dybly AG, H1 2016 46
Hypercholesterolemia - Pipeline by Eli Lilly and Company, H1 2016 47
Hypercholesterolemia - Pipeline by Esperion Therapeutics, Inc., H1 2016 48
Hypercholesterolemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 49
Hypercholesterolemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 50
Hypercholesterolemia - Pipeline by Immune Response BioPharma, Inc., H1 2016 51
Hypercholesterolemia - Pipeline by Johnson & Johnson, H1 2016 52
Hypercholesterolemia - Pipeline by Kadmon Corporation, LLC, H1 2016 53
Hypercholesterolemia - Pipeline by Kastle Therapeutics, LLC, H1 2016 54
Hypercholesterolemia - Pipeline by Kowa Company, Ltd., H1 2016 55
Hypercholesterolemia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 56
Hypercholesterolemia - Pipeline by Merck & Co., Inc., H1 2016 57
Hypercholesterolemia - Pipeline by Omeros Corporation, H1 2016 58
Hypercholesterolemia - Pipeline by Pfizer Inc., H1 2016 59
Hypercholesterolemia - Pipeline by Planet Biotechnology Inc., H1 2016 60
Hypercholesterolemia - Pipeline by Progenra, Inc., H1 2016 61
Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 62
Hypercholesterolemia - Pipeline by RegenxBio Inc., H1 2016 63
Hypercholesterolemia - Pipeline by Serometrix, LLC, H1 2016 64
Hypercholesterolemia - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016 65
Hypercholesterolemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016 66
Hypercholesterolemia - Pipeline by Viking Therapeutics, Inc., H1 2016 67
Hypercholesterolemia - Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H1 2016 68
Assessment by Monotherapy Products, H1 2016 69
Assessment by Combination Products, H1 2016 70
Number of Products by Stage and Target, H1 2016 72
Number of Products by Stage and Mechanism of Action, H1 2016 77
Number of Products by Stage and Route of Administration, H1 2016 81
Number of Products by Stage and Molecule Type, H1 2016 83
Hypercholesterolemia Therapeutics - Recent Pipeline Updates, H1 2016 177
Hypercholesterolemia - Dormant Projects, H1 2016 225
Hypercholesterolemia - Dormant Projects (Contd..1), H1 2016 226
Hypercholesterolemia - Dormant Projects (Contd..2), H1 2016 227
Hypercholesterolemia - Dormant Projects (Contd..3), H1 2016 228
Hypercholesterolemia - Dormant Projects (Contd..4), H1 2016 229
Hypercholesterolemia - Dormant Projects (Contd..5), H1 2016 230
Hypercholesterolemia - Discontinued Products, H1 2016 231
Hypercholesterolemia - Discontinued Products (Contd..1), H1 2016 232